Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

This study has been terminated.
Information provided by:
Beth Israel Medical Center Identifier:
First received: January 9, 2006
Last updated: October 31, 2007
Last verified: January 2006
To study the effectiveness and safety of adding Rosiglitazone, an insulin sensitizing agent to people with chronic hepatitis C infection genotype 1 with fatty liver disease, who are being treated with standard therapy. Standard therapy consists of weekly pegylated interferon injections and daily ribavirin pills, whose dosage is weight based. This regimen in genotype 1 patients is effective in only 45% of patients at best. In addition, this therapy must be given for 48 weeks to be effective and has alot of side-effects. One risk factor for a poor response is fatty liver. Rosiglitazone has been shown to be effective in the treatment of patients with fatty liver alone. This study hopes to show that the addition of Rosiglitazone to the standard therapy in genotype 1 patients with fatty liver disease will increase effectiveness of the standard therapy of hepatitis C.

Condition Intervention Phase
Chronic Hepatitis C Infection
Fatty Liver
Drug: Rosiglitazone and Pegasys/Ribavirin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Randomized Placebo-Control Pilot Study Evaluating the Efficacy and Safety of Rosiglitazone Combined With Pegylated Interferon Plus Ribavirin Versus Pegylated Interferon Plus Ribavirin Alone in Genotype 1 Hepatitis C With Steatosis

Resource links provided by NLM:

Further study details as provided by Beth Israel Medical Center:

Primary Outcome Measures:
  • To compare the efficacy of Rosiglitazone in combination with pegylated interferon alfa-2a and ribavirin (weight-based) to that of pegylated interferon alfa-2a and ribavirin alone in terms of sustained viral response.

Secondary Outcome Measures:
  • To compare the safety and tolerability of Rosiglitazone in combination with pegylated interferon-2a and ribavirin to that of pegylated interferon alfa-2a and ribavirin alone in terms of adverse events.

Estimated Enrollment: 30
Study Start Date: January 2006
Study Completion Date: October 2007
Detailed Description:

Eligible thirty subjects will be randomized in a double blinded fashion to either Rosiglitazone 4mg pills twice a day versus placebo for six weeks. Then after this six week period, both groups will be treated for 48 weeks of standard therapy for hepatitis C consisting of Pegasys 180mcq weekly injections with Ribavirin 1,000mg-1,200mg daily depending if the subject weights less than 75 kg will then receive the lower dosage. In addition, the subjects will be continued on Rosiglitazone or placebo for the 48 weeks.

The subjects will be monitored for side-effects by history taking and blood testing at predetermined time periods during the study. If the viral load has not dropped more than two log at week 12 of standard therapy for hepatitis C then therapy will be stopped and the subject is considered a treatment failure. Similarly, if there was a greater than two log drop in the viral load at week 12 but there is still virus present in the blood at week 24 then therapy is stopped and the subject is considered treatment failure. If the virus is undetectable in the blood at week 12 and 24 then therapy is continued for the full 48 weeks. If the virus is detectable at week 48 then the subject is considered a treatment failure.

After this 48 week treatment period and the virus is still undetectable, there is a follow-up period consisting of 24 weeks off therapy. At the end of the 24 weeks, blood will be tested for the virus and if the virus is not present then the subject has a sustained viral response and is a treatment success.

During therapy if the subject becomes significantly anemic Procrit 40,000Units weekly injections will be started. Similarly, if the white blood cell count drops below a certain level then weekly Neupogen 300mcq injections will be started. In addition, if there is mild depressive symptoms treatment will be started but if there is major depressive symptoms, then therapy will be stopped and a referral to a psychiatrist will be made.


Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women at least 21 years of age.
  • Positive serum hepatitis C RNA for at least 6 months.
  • Naive to any therapy for hepatitis C infection.
  • Significant steatosis or fat on the liver biopsy.
  • Genotype 1 patients.

Exclusion Criteria:

  • Subjects with decompensated liver disease.
  • Hemoglobin <12g/dl.
  • WBC<2,000mm3.
  • ANC<1,000mm3.
  • Platelet count<50,000/mm3.
  • Creatinine>1.5mg/dl.
  • Albumin<2.5g/dl.
  • Bilirubin>4mg/dl.
  • HIV or hepatitis B co-infection.
  • History of other liver disease besides fatty liver disease.
  • History of unstable cardiac or cerebrovascular disease.
  • History of significant psychiatric disorders.
  • Alcohol or drug abuse within last year.
  • Pregnant or lactating women or men whose sexual partner is pregnant or lactating.
  • Taking of insulin or oral hypoglycemic agents within six months of the study.
  • Uncontrolled thyroid disorder.
  • History of malignancy within the past 5 years unless cured by surgery.
  • History of autoimmune disorder or organ transplantations requiring immunosuppression.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00274495

United States, New York
Beth Israel Medical Center - Philipps Ambulatory Care Center
New York, New York, United States, 10003
Sponsors and Collaborators
Beth Israel Medical Center
Principal Investigator: Douglas Meyer, M.D. Beth Israel Medical Center
Study Director: Henry C. Bodenheimer, M.D. Beth Israel Medical Center
  More Information Identifier: NCT00274495     History of Changes
Other Study ID Numbers: 098-04
Study First Received: January 9, 2006
Last Updated: October 31, 2007

Keywords provided by Beth Israel Medical Center:
Genotype 1
Metabolic syndrome
Insulin resistance

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Fatty Liver
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 21, 2017